deltatrials
Terminated PHASE4 NCT00720902

Adult Growth Hormone Deficiency and Cardiovascular Risk

Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas

Sponsor: Columbia University

Conditions Growth Hormone Deficiency
Interventions Blood draws Carotid ultrasound Endothelial cell biopsy MRI growth hormone releasing hormone (GHRH) & arginine
Updated 7 times since 2017 Last updated: Oct 24, 2022 Started: Feb 28, 2007 Primary completion: Mar 31, 2010 Completion: May 31, 2011

Listed as NCT00720902, this PHASE4 trial focuses on Growth Hormone Deficiency and remains terminated or withdrawn. Sponsored by Columbia University, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Dec 2022 — Jul 2024 [monthly]

    Terminated PHASE4

    Phase: NA → PHASE4

  4. Jan 2021 — Dec 2022 [monthly]

    Terminated NA

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated NA

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated NA

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated NA

    First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Columbia University
Data source: Columbia University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States